Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis

Table 3 Treatment in each group ^a

Treatments	DM with A/SIP	DM with CIP	DM without ILD
Number of patients	17	24	16
PSL or other agent alone, n (%)	3 (18)	8 (33)	12 (75)**
PSL	3	7	11
CNI	0	1	0
AZA	0	0	1
PSL + other agents, n (%)	14 (82)	16 (67)	3 (19)**
CNI	9	13	1
MTX	0	0	2
IVCY	0	1	0
CNI + MZB	0	1	0
CNI + IVCY	3	0	0
HSCT	2	1	0

^aA/SIP, Acute/subacute interstitial pneumonia; AZA, Azathioprine; CIP, Chronic interstitial pneumonia; CNI, Calcineurin inhibitor (cyclosporine or tacrolimus); DM, Dermatomyositis; HSCT, Hematopoietic stem cell transplant; ILD, Interstitial lung disease; IVCY, Intravenous pulse cyclophosphamide; MTX, Methotrexate; MZB, Mizoribine; PSL, Prednisolone. **P <0.01 compared with DM with A/SIP using Fisher’s exact test.

ISSN: 1478-6362